65 results
SC 13E3/A
EX-99
STSA
Satsuma Pharmaceuticals Inc
8 Jun 23
Going private transaction (amended)
9:16am
of the CVRs (including the cost of any transfer tax) will be the responsibility of the transferor; provided that the Rights Agent shall not impose a service … the later of (i) the fifth anniversary of the Closing Date, and (ii) the latest time that payment of such CVR Payment Amount would not result in a Tax
SC 14D9/A
STSA
Satsuma Pharmaceuticals Inc
24 May 23
Tender offer solicitation (amended)
9:40pm
manager, accountant, lawyer or other professional advisor. The Unaffiliated Stockholders are advised that acceptance of the Offer may have tax … consequences and that they should consult their tax advisors.
Substantive Fairness
Item 8
Additional Information.
Item 8. “Additional Information
SC 14D9
STSA
Satsuma Pharmaceuticals Inc
5 May 23
Tender offer solicitation
8:17am
cash amounts that the Company’s executive officers and non-employee directors are eligible to receive (before deduction of applicable tax withholding … to the excise tax imposed by Section 4999 of the U.S. Internal Revenue Code, the executive would receive the full amount of the payments and benefits
8-K
EX-2.1
hlxh 0bw8
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
8-K
EX-10.1
cgjrxgo
17 Apr 23
SNBL to Acquire Satsuma Pharmaceuticals
6:34am
8-K
EX-1.1
ydp0z2f mwlc
3 Nov 22
Entry into a Material Definitive Agreement
4:45pm
424B5
9y6cp
3 Nov 22
Prospectus supplement for primary offering
4:42pm
8-K
EX-99.1
myiqehp7r1mb 844el
3 Nov 22
Satsuma Pharmaceuticals Reports Third Quarter 2022 Financial Results and Recent Business Highlights
4:00pm
8-K
EX-99.1
dpp62sj9tgp3a1cp0p43
10 May 22
Satsuma Pharmaceuticals Reports First Quarter 2022 Financial Results
4:02pm
424B3
ccxwfc
6 May 21
Prospectus supplement
12:00am